FOSTER CITY, Calif. (AP) ¿ SciClone Pharmaceuticals Inc. said Friday it has stopped a trial of a late-stage pancreatic cancer drug candidate after analyzing data from the trial.
A data safety monitoring committee recommended the trial of RP101 be stopped, SciClone said. The company will evaluate data from the study.
In aftermarket trading, shares of the biotech drugmaker lost 48 cents, or 11.6 percent, to $3.67. The stock closed at $4.15 in the regular session.